New, long-acting, potent bradykinin antagonists
نویسندگان
چکیده
منابع مشابه
Nonpeptide mimic of bradykinin with long-acting properties.
Kinins, members of a family of peptides released from kininogens by the action of kallikreins, have been implicated in a variety of biological activities including vasodilation, increased vascular permeability, contraction of smooth muscle cells and activation of sensory neurons. However, investigation of the physiological actions of kinins have been greatly hampered because its effects are cur...
متن کاملAntagonists of B2 bradykinin receptors.
Bradykinin and its active metabolites, produced by kallikreins at their sites of action, potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, cytokine release, and eicosanoid formation. These effects are mediated by at...
متن کاملNarcotic Antagonists: The Search for Long-Acting Preparations, 4
S 7 DEVELOPMENT OF POLYLACTIC/GLYCOLIC ACID DELIVERY SYSTEMS FOR USE IN TREATMENT OF NARCOTIC ADDICTION A.D. Schwope, D.L. Wise, J.F. Howes 13 DEVELOPMENT OF INJECTABLE MICROCAPSULES FOR USE IN THE TREATMENT OF NARCOTIC ADDICTION C. Thies 19 LONG-ACTING NARCOTIC ANTAGONIST COMPLEXES A.P. Gray, W.J. Guardina 21 SUSTAINED RELEASE OF NALTREXONE FROM GLYCERIDE IMPLANTS M.F. Sullivan, D.R. Kalkwarf ...
متن کاملEngineering potent long-acting variants of the Wnt inhibitor DKK2
Wnt signaling pathways are required for a wide variety of biological processes ranging from embryonic development to tissue repair and regeneration. Dickkopf-2 (DKK2) is classically defined as a canonical Wnt inhibitor, though it may play a role in activating non-canonical Wnt pathways in the context of endothelial network formation after acute injury. Here we report the discovery of a fusion p...
متن کاملPharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists. At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma luteinizing hormone (LH) and testosteron...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Pharmacology
سال: 1991
ISSN: 0007-1188
DOI: 10.1111/j.1476-5381.1991.tb12169.x